US and UK agree zero tariffs deal on pharmaceuticals

The UK and US struck a three‑year deal keeping US import tariffs on UK pharmaceuticals at zero in exchange for the UK accepting higher drug prices for the NHS and committing to increase NHS drug spending (targeting 0.3% to 0.6% of GDP over 10 years) and raising the price threshold for new treatments by 25%; manufacturer payback caps will be set at 15% (down from >20% last year). The agreement protects roughly £11.1bn of UK medicine exports to the US (17.4% of UK goods exports to the US over the last 12 months) and is presented as a lever to secure investment—several majors have already signalled or redirected multibillion-dollar US investments—while raising near‑term fiscal pressure on the UK health budget.

Analysis

Market structure: The deal is a clear near-term win for UK-based pharma exporters (GSK, mid-cap CMOs, life‑science real‑estate) because it removes a tariff tail‑risk for three years and improves pricing power via NICE's 25% higher cost‑threshold and a lower manufacturer payback cap (15% vs >20%). Expect upward earnings revisions for UK-listed drug makers selling into the US (order-of-magnitude: protects ~£11bn pa exports) and a compression of pharma equity volatility; conversely, US onshoring beneficiaries and short‑cycle service providers tied to tariffs lose optionality. Cross‑asset: equities (UK pharma) ticket higher, implied vols fall, near-term GBP receives modest support; Gilts may face incremental supply pressure over medium-term if Treasury funds ~£3bn+ extra drug spend, pushing short‑end yields wider by tens of bps if financed aggressively.

Risk assessment: Tail risks include policy reversal (Trump or US admin reneging after three years), a UK political backlash reversing the pricing concessions, or unexpected NICE/clinical setbacks that keep approvals muted; each could shave 10–30% off re-rated equity gains. Immediate (days): risk premium compression; short (weeks–months): capex announcements and NICE approval cadence (3–5 extra approvals pa) will drive stock moves; long (3+ years): structural onshoring trends and fiscal funding needs determine ultimate capex location. Hidden dependencies: companies may still prefer US investment for tax, talent and market access despite tariff certainty; supply‑chain resilience and clinical readouts remain dominant drivers.

Trade implications: Direct long: establish a 2–3% long position in GSK (ticker GSK) with a 6–12 month horizon to capture tariff relief and anticipated capex/earnings upgrades; hedge execution risk with a 6–9 month call spread (buy 15–20% OTM call, sell 30% OTM). Pair trade: long GSK / short AZN 1:1 for 3–9 months (UK‑export exposure vs global/US‑pivot exposure) to isolate UK policy premium. Macro: take a small (0.5–1% NAV) long GBP forward position for 3–12 months to ride trade‑stability while capping duration exposure by underweighting 5–10% of nominal gilts duration exposure.

Contrarian angles: Consensus underestimates fiscal and political friction — the market may be underpricing the chance that higher NHS drug spend triggers later price controls or renegotiation (>20% payback reintroduced), which would compress margins. The near‑term rally may be overdone for smaller UK biotech names whose commercialization depends on NHS budgets rather than exports; historically (tariff threats in metals/agriculture) negotiations removed headline threats but did not halt strategic capex shifts to the US. Set stop/triggers: cut longs if NICE approval cadence stalls below +2 incremental approvals/yr or if GBP falls >3% from entry, and book profits if GSK rallies >25% in 3 months absent fundamental upside.

Key Decisions for Investors

• Establish a 2–3% long position in GSK (GSK) equity with a 6–12 month horizon to capture tariff‑risk derisking; hedge tail risk by buying a 6–9 month 15–20% OTM call spread sized to cap premium to ~25–30% of the equity position.
• Implement a relative‑value pair: long GSK / short AZN 1:1 (equal notional) for 3–9 months to isolate UK tariff premium; trim or unwind if AZN outperforms GSK by >10% or if GSK rises >20% without fundamental drivers.
• Allocate 0.5–1% NAV to a 3–12 month GBP forward (long GBP) to capture near‑term FX support from trade certainty, while simultaneously reducing UK sovereign duration exposure by 0.5–1 year (underweight 5–10% of gilt duration).
• Avoid small‑cap UK biotech longs dependent solely on NHS uptake; instead rotate 1–2% NAV into UK contract manufacturing or life‑science real‑estate plays that benefit from export volume stability; exit if projected NHS incremental drug spend exceeds £5bn pa or if payback cap is increased above 15%.